Early-Stage Breast CancerNCT00233077
Patient Centered Randomized Controlled Trial
A study testing Patient Assistance and Information only in people with Early-Stage Breast Cancer, run by Icahn School of Medicine at Mount Sinai at 8 sites in United States.
Trial summary
The purpose of this study is to determine whether patient-assistance programs as compared with usual care will help women with early stage breast cancer receive appropriate treatments. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Early-Stage Breast Cancer
- What is being tested?
- Patient Assistance and Information only
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 374 participants
- Where
- 8 sitesUnited States
- Study dates
- Oct 2006to Jan 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients, who are English or Spanish speaking, with a new primary stage 1 or 2 breast cancer who have undergone either breast conserving surgery or mastectomy and those with tumors >1cm or <1cm and poorly differentiated;
- All surgeons performing breast surgery at the participating hospitals
Who cannot join
- Patients with dementia or those with a poor prognosis due to end-stage organ failure or other concomitant conditions such as those undergoing treatment for other cancers
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
United States8 sites
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Metropolitan Hospital
New York, New York, 10029
Columbia University
New York, New York, 10032
Harlem Hospital Center
New York, New York, 10037
Albert Einstein College of Medicine
New York, New York, 10461
Montefiore Medical Center
New York, New York, 10467
Elmhurst Hospital Center
Queens, New York, 11373
Queens Hospital Center
Queens, New York, 11432
About this study
Official title: Patient Assistance to Reduce Breast Cancer Disparities
The purpose of this study is to determine whether patient-assistance programs as compared with usual care will help women with early stage breast cancer receive appropriate treatments.
Read the detailed description
Numerous trials proved the efficacy of radiation following breast conserving surgery and systemic therapies to increase disease-free and overall survival among women with early-stage breast cancer. Yet 14%-89% of women do not receive them, especially minority women. Despite lower incidence of the disease, African American women are more likely than white women to die of breast cancer. As we near racial equity in rates of breast cancer screening, disparities in treatment and mortality remain. Efforts to achieve control of breast cancer and reduce racial disparities in mortality will not be fully realized until proven effective treatments are provided to those who can benefit.
Underuse of effective treatments may be caused by patient, physician and system factors. For breast cancer screening, women's lack of access to care; insurance; transportation; beliefs about fatalism and curability, and cancer's effect on partner relationships, all impact mammography rates. For breast cancer treatment, little is known about patient-related reasons for underuse, and less is known about racial differences in such reasons.
Interventions targeted to specific causes are more likely to succeed. For breast cancer screening, patient-centered interventions that successfully raise mammography rates among minority women include lay health workers to raise awareness about and address cultural beliefs and barriers to screening, vouchers to pay for screening and navigators to help women with abnormal screenings obtain needed follow-up. For breast cancer treatment, patient-assistance programs provide practical support such as financial counseling, aid with navigating the complex healthcare system, emotional support, and information about cancer and its treatment. Such programs abound but patients are often unaware of them. While these services may increase the receipt of effective adjuvant therapies, these strategies have not been rigorously tested.
We propose to conduct a randomized controlled trial to evaluate the effectiveness of patient-assistance programs as compared with usual care on receipt of adjuvant therapies among minority and nonminority women with newly operated early-stage breast cancer. During the 24 month trial, we will assess patients' beliefs about cancer and its treatment, and their practical, psychosocial, and informational needs and barriers to care. We will identify and train employees in existing cancer assistance services in order to increase the sustainability of this program beyond the grant-funded cycle. Specifically, we propose:
- To assess racial differences in early-stage breast cancer patients' experiences, beliefs about and barriers to effective adjuvant treatments;
- To evaluate the effectiveness of an intervention connecting women with early-stage breast cancer and cancer-related needs to community and hospital-based patient-assistance programs to reduce underuse of effective adjuvant breast cancer treatment overall and in minority populations and to assess its sustainability; and
- To evaluate whether this patient assistance intervention affects patients' knowledge, attitudes and behaviors
- Conditions
- Early-Stage Breast Cancer
- Being tested
- Patient Assistance, Information only
- Keywords
- breast cancer, adjuvant treatment, racial disparities
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient AssistanceBehavioural
Patients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
Information onlyBehavioural
Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
| Study group | Role | What they receive |
|---|---|---|
| Behavioral: Patient Assistance | Experimental | Patient assistance programs Receives: Behavioral: Patient Assistance |
| Control: Information only | Other | Control patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again. Receives: Behavioral: Information only |
What is being measured
The primary outcome is the main question the study is designed to answer.
initiation and completion of primary treatment
Measured: Measured after completion of 6-mth interview
Secondary outcomes (5)
adherence
Measured: Measured after completion of 6-mth interview
emotional and health status
Measured: Measured at baseline
emotional and health status
Measured: Measured after completion of 6-mth interview
patient satisfaction
Measured: measured at baseline
patient satisfaction
Measured: Measured after completion of 6-mth interview
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2005 (estimated)
- Study startOct 2006
- Primary completionJun 2010
- Study completionJan 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Early-Stage Breast CancerStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 374 participants (actual)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Nina A Bickell, MD, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00233077
- Sponsor's protocol ID
- GCO 03-0593
- Other IDs
- 1R01CA10705-01A1
- Status last verified
- Dec 2013
- First submitted
- 3 Oct 2005
- Last updated
- 3 Dec 2013
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Guth AA, Fineberg S, Fei K, Franco R, Bickell NA. Utilization of Oncotype DX in an Inner City Population: Race or Place? Int J Breast Cancer. 2013;2013:653805. doi: 10.1155/2013/653805. Epub 2013 Dec 18.
PubMed 24455283Bickell NA, Geduld AN, Joseph KA, Sparano JA, Kemeny MM, Oluwole S, Menes T, Srinivasan A, Franco R, Fei K, Leventhal H. Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer? J Oncol Pract. 2014 Jan;10(1):48-54. doi: 10.1200/JOP.2013.000920. Epub 2013 Sep 10.
PubMed 24023271Lin JJ, Fei K, Franco R, Bickell NA. Breast cancer patients' recall of receiving patient assistance services. Springerplus. 2012 Oct 3;1:24. doi: 10.1186/2193-1801-1-24. eCollection 2012.
PubMed 23961354
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Assistance to Reduce Breast Cancer Disparities
- ClinicalTrials.gov ID
- NCT00233077
- Acronym / sponsor ID
- GCO 03-0593
- Conditions
- Early-Stage Breast Cancer
- Keywords
- breast cancer, adjuvant treatment, racial disparities
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 374 participants (actual)
- Lead sponsor
- Icahn School of Medicine at Mount SinaiUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Oct 2006
- Primary completion
- Jun 2010 (actual)
- Study completion
- Jan 2011 (actual)
- First posted
- 5 Oct 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether patient-assistance programs as compared with usual care will help women with early stage breast cancer receive appropriate treatments.
Detailed description
Numerous trials proved the efficacy of radiation following breast conserving surgery and systemic therapies to increase disease-free and overall survival among women with early-stage breast cancer. Yet 14%-89% of women do not receive them, especially minority women. Despite lower incidence of the disease, African American women are more likely than white women to die of breast cancer. As we near racial equity in rates of breast cancer screening, disparities in treatment and mortality remain. Efforts to achieve control of breast cancer and reduce racial disparities in mortality will not be fully realized until proven effective treatments are provided to those who can benefit.
Underuse of effective treatments may be caused by patient, physician and system factors. For breast cancer screening, women's lack of access to care; insurance; transportation; beliefs about fatalism and curability, and cancer's effect on partner relationships, all impact mammography rates. For breast cancer treatment, little is known about patient-related reasons for underuse, and less is known about racial differences in such reasons.
Interventions targeted to specific causes are more likely to succeed. For breast cancer screening, patient-centered interventions that successfully raise mammography rates among minority women include lay health workers to raise awareness about and address cultural beliefs and barriers to screening, vouchers to pay for screening and navigators to help women with abnormal screenings obtain needed follow-up. For breast cancer treatment, patient-assistance programs provide practical support such as financial counseling, aid with navigating the complex healthcare system, emotional support, and information about cancer and its treatment. Such programs abound but patients are often unaware of them. While these services may increase the receipt of effective adjuvant therapies, these strategies have not been rigorously tested.
We propose to conduct a randomized controlled trial to evaluate the effectiveness of patient-assistance programs as compared with usual care on receipt of adjuvant therapies among minority and nonminority women with newly operated early-stage breast cancer. During the 24 month trial, we will assess patients' beliefs about cancer and its treatment, and their practical, psychosocial, and informational needs and barriers to care. We will identify and train employees in existing cancer assistance services in order to increase the sustainability of this program beyond the grant-funded cycle. Specifically, we propose:
- To assess racial differences in early-stage breast cancer patients' experiences, beliefs about and barriers to effective adjuvant treatments;
- To evaluate the effectiveness of an intervention connecting women with early-stage breast cancer and cancer-related needs to community and hospital-based patient-assistance programs to reduce underuse of effective adjuvant breast cancer treatment overall and in minority populations and to assess its sustainability; and
- To evaluate whether this patient assistance intervention affects patients' knowledge, attitudes and behaviors
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Behavioral: Patient Assistance | Experimental | Behavioral: Patient AssistancePatient assistance programs |
| Control: Information only | Other | Behavioral: Information onlyControl patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- All patients, who are English or Spanish speaking, with a new primary stage 1 or 2 breast cancer who have undergone either breast conserving surgery or mastectomy and those with tumors >1cm or <1cm and poorly differentiated;
- All surgeons performing breast surgery at the participating hospitals
Key exclusion criteria (1 listed)
- Patients with dementia or those with a poor prognosis due to end-stage organ failure or other concomitant conditions such as those undergoing treatment for other cancers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient AssistancePatients will be surveyed to assess their knowledge about cancer \& its treatment, experience with \& access to health care system, trust, depression, social support \& self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs. | Behavioural | Behavioral: Patient Assistance |
| Information onlyControl patients will be sent a pamphlet about breast cancer \& its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again. | Behavioural | Control: Information only |
Primary outcome
initiation and completion of primary treatment
Time frame: Measured after completion of 6-mth interview
5 secondary outcomes
adherence
Time frame: Measured after completion of 6-mth interview
emotional and health status
Time frame: Measured at baseline
emotional and health status
Time frame: Measured after completion of 6-mth interview
patient satisfaction
Time frame: measured at baseline
patient satisfaction
Time frame: Measured after completion of 6-mth interview
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2013.
- Derived from this study: PubMed 24455283Guth AA, Fineberg S, Fei K, Franco R, Bickell NA. Utilization of Oncotype DX in an Inner City Population: Race or Place? Int J Breast Cancer. 2013;2013:653805. doi: 10.1155/2013/653805. Epub 2013 Dec 18.
- Derived from this study: PubMed 24023271Bickell NA, Geduld AN, Joseph KA, Sparano JA, Kemeny MM, Oluwole S, Menes T, Srinivasan A, Franco R, Fei K, Leventhal H. Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer? J Oncol Pract. 2014 Jan;10(1):48-54. doi: 10.1200/JOP.2013.000920. Epub 2013 Sep 10.
- Derived from this study: PubMed 23961354Lin JJ, Fei K, Franco R, Bickell NA. Breast cancer patients' recall of receiving patient assistance services. Springerplus. 2012 Oct 3;1:24. doi: 10.1186/2193-1801-1-24. eCollection 2012.
Related trials for Early-Stage Breast Cancer
RecruitingPhase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
RecruitingPhase 2
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Breast Cancer
Active, not recruitingPhase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Recruiting
Evaluation of the Effect of Regular Physical Exercise in Breast Cancer.
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Not yet recruiting
PRISM Trial: Partial Breast Versus Whole Breast Radiation in Early Breast Cancer
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nina A Bickell, MD principal investigator
Icahn School of Medicine at Mount Sinai
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Patient Assistance and Information only in people with Early-Stage Breast Cancer, run by Icahn School of Medicine at Mount Sinai at 8 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
initiation and completion of primary treatment (time frame: Measured after completion of 6-mth interview). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00233077, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2013.